Nov 28, 2019: The National Institute for Health and Care Excellence (NICE) approves Pfizer’s Ibrance (palbociclib), through the Cancer Drugs Fund (CDF), for use in combination with fulvestrant for the treatment of women who have hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer, who have inwarded prior endocrine therapy. This is based on data from the Phase III clinical trial, PALOMA-3, which shows that Ibrance delayed disease progression by 6.6 months, compared to fulvestrant alone.
This breakthroughs in breast cancer therapy will be very useful of more than 3,200 women in England living with advanced HR+, HER2- breast cancer will now be eligible for the treatment. https://www.nice.org.uk/guidance/ta495/documents/final-appraisal-determination-document
